Zebularine Ameliorates Imiquimod‐Induced Psoriasis by Inhibiting Oxidative Stress and Inflammation With Concomitant Inhibition of NF‐κB/MAPK and DNMT1
Journal of Biochemical and Molecular Toxicology · 2025
DOI: 10.1002/jbt.70364 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2025. Verfasst von Ankita Sood und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Epigenetics and Diseases, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, SAS N…. Hauptthemen laut MEDLINE: Imiquimod, Psoriasis, DNA (Cytosine-5-)-Methyltransferase 1, Cytidine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: The authors are grateful to the National Institute of Pharmaceutical Education and Research, S.A.S Nagar, and the Department of Pharmaceuticals, Ministry of Ch….
Abstract (Originalsprache)
In this study, we evaluated the impact of a potent DNA methyl transferase (DNMT) inhibitor zebularine on imiquimod‐induced psoriatic mice, revealing its efficacy in mitigating hyperproliferation and keratinocyte differentiation. Molecular analyses demonstrated a marked inhibition of p38, ERK, and JNK signaling pathways, accompanied by a notable reduction in proliferative markers such as Ki‐67. The crucial regulator of keratinocyte proliferation, Ki‐67, exhibited significant downregulation upon zebularine treatment. Moreover, significant anti‐inflammatory effects were evident through the suppression of the imiquimod‐induced p65 NF‐κB signaling cascade. This robust inhibition extended to the reduction in the cytokine storm associated with psoriasis‐like skin inflammation. Consequently, there was a restoration of the normal epidermal architecture, accompanied by a decrease in epidermal hyperplasia and splenomegaly. Importantly, zebularine's inhibition of DNMT1 underscores its role in modulating epigenetic pathways. By altering DNA methylation, zebularine might effectively inhibit the expression of genes responsible for both inflammation and proliferation, contributing to improved skin structure. These findings collectively highlight zebularine's potential as a therapeutic agent in the management of psoriasis, supported by its anti‐inflammatory effects and observed inhibition of DNMT1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Epigenetics and Diseases, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, SAS Nagar, Punjab, India.
ORCID-Profile: Kulbhushan Tikoo
Förderung
- The authors are grateful to the National Institute of Pharmaceutical Education and Research, S.A.S Nagar, and the Department of Pharmaceuticals, Ministry of Ch…
Zitieren
APA
Sood, A., Chintalapani, S., Sharma, S., & Tikoo, K. (2025). Zebularine Ameliorates Imiquimod‐Induced Psoriasis by Inhibiting Oxidative Stress and Inflammation With Concomitant Inhibition of NF‐κB/MAPK and DNMT1. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.70364
Vancouver
Sood A, Chintalapani S, Sharma S, Tikoo K. Zebularine Ameliorates Imiquimod‐Induced Psoriasis by Inhibiting Oxidative Stress and Inflammation With Concomitant Inhibition of NF‐κB/MAPK and DNMT1. Journal of Biochemical and Molecular Toxicology. 2025. doi:10.1002/jbt.70364
BibTeX
@article{Sood2025,
author = {Sood, Ankita and Chintalapani, Srinidhi and Sharma, Shivam and Tikoo, Kulbhushan},
title = {Zebularine Ameliorates Imiquimod‐Induced Psoriasis by Inhibiting Oxidative Stress and Inflammation With Concomitant Inhibition of NF‐κB/MAPK and DNMT1},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2025},
doi = {10.1002/jbt.70364}
}
EUVIMED